Kanaly Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kanaly Trust’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$0	Sell	6 -23	-79%	-$1.98K	﹤0.01%	921
2016 Q3	$3K	Buy	29 +23	+383%	+$2.17K	﹤0.01%	709
2016 Q2	$0	Hold	6	–	–	﹤0.01%	903
2016 Q1	$0	Buy	+6	New	+$488	﹤0.01%	879
2015 Q3	–	Sell	-14	Closed	-$2K	–	877
2015 Q2	$2K	Hold	14	–	–	﹤0.01%	757
2015 Q1	$2K	Hold	14	–	–	﹤0.01%	598
2014 Q4	$1K	Hold	14	–	–	﹤0.01%	673
2014 Q3	$1K	Buy	+14	New	+$920	﹤0.01%	769
2014 Q2	–	Sell	-18	Closed	-$1K	–	716
2014 Q1	$1K	Buy	+18	New	+$1.33K	﹤0.01%	659

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kanaly Trust's BMRN Position: Q4 2016 in Review

Kanaly Trust reduced its BioMarin Pharmaceuticals (BMRN) stake by 79% in Q4 2016, selling an estimated $1.98K and leaving 6 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #921.

Kanaly Trust first reported a position in BMRN in Q1 2014 and has held it in 9 quarters since. The position peaked at $3K in Q3 2016. 414 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

Kanaly Trust held 6 shares of BioMarin Pharmaceuticals worth $0 as of Q4 2016.
Kanaly Trust sold 23 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $1.98K.
BioMarin Pharmaceuticals made up ﹤0.01% of Kanaly Trust's portfolio in Q4 2016, its #921 holding.
Kanaly Trust first reported a position in BioMarin Pharmaceuticals in Q1 2014 and has held it in 9 quarters since.
Kanaly Trust's BioMarin Pharmaceuticals position peaked at $3K in Q3 2016.
414 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Kanaly Trust's 13F filing for Q4 2016, filed 23 Jan 2017.